Temodar Clinical Trials Temodar RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
Condition:   Recurrent Extensive Stage Small Cell Lung Carcinoma Interventions:   Drug: HTMC0435;   Drug: Temozolomide Sponsor:   Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
Condition:   Glioblastoma Intervention:   Drug: Pembrolizumab and Temozolomide Sponsor:   University of Louisville Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2023 Category: Research Source Type: clinical trials

A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma
Conditions:   Recurrent High Grade Glioma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Glioblastoma;   Gliosarcoma Interventions:   Drug: PCI 24781;   Drug: Temozolomide Sponsors:   University of Nebraska;   Xynomic Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
Condition:   Glioblastoma Intervention:   Drug: Pembrolizumab and Temozolomide Sponsor:   University of Louisville Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2023 Category: Research Source Type: clinical trials

A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma
Conditions:   Recurrent High Grade Glioma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Glioblastoma;   Gliosarcoma Interventions:   Drug: PCI 24781;   Drug: Temozolomide Sponsors:   University of Nebraska;   Xynomic Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
Condition:   Glioblastoma Intervention:   Drug: Pembrolizumab and Temozolomide Sponsor:   University of Louisville Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2023 Category: Research Source Type: clinical trials

A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma
Conditions:   Recurrent High Grade Glioma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Glioblastoma;   Gliosarcoma Interventions:   Drug: PCI 24781;   Drug: Temozolomide Sponsors:   University of Nebraska;   Xynomic Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2023 Category: Research Source Type: clinical trials